Новостная лента

• Hancock Jaffe Announces Intention to Merge with Catheter Precision

  Yahoo

  01 июн 2020 г. в 12:30

  IRVINE, CA / ACCESSWIRE / June 1, 2020 / Hancock Jaffe Laboratories, Inc. (HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Company has signed a non-binding letter of intent to merge with Catheter Precision, Inc., a private medical device company focused on cardiovascular diseases, including heart arrythmias. Catheter Precision has developed a software imaging system called VIVO™, an initial version of which is FDA cleared and CE marked, and that produces a 3-D virtual image of the heart on a computer monitor for the purpose of accurately identifying and targeting the anatomical location of ventricular arrhythmias for catheter ablation therapy. Ventricular arrhythmias are commonly associated with sudden cardiac death, which accounts for approximately 325,000 fatalities in the U.S. each year.

• Hancock Jaffe Announces Plans for CoreoGraft First-in-Human Study

  Yahoo

  12 мая 2020 г. в 12:30

  IRVINE, CA / ACCESSWIRE / May 12, 2020 / Hancock Jaffe Laboratories, Inc. (HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Company has received approval from the Superintendent of Health of the National Health Counsel for the Republic of Paraguay to conduct a first-in-human study for its CoreoGraft bioprosthetic graft. The first-in-human study will initially consist of five patients who will receive CoreoGrafts as part of their coronary artery bypass graft ("CABG") surgeries. The CoreoGraft patients will be monitored for a one-year period post CoreoGraft surgery, with interim results reported at 30, 90, 180, and 365 days.

• Hancock Jaffe Announces One Year Follow-up Data on VenoValve Patients

  Yahoo

  28 апр 2020 г. в 14:30

  IRVINE, CA / ACCESSWIRE / April 28, 2020 / Hancock Jaffe Laboratories, Inc. (HJLI)(HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that five VenoValve patients from HJLI's first-in-man, clinical study in Colombia have now reached the one-year milestone following VenoValve surgery, and that chronic venous insufficiency ("CVI") has significantly improved in all five patients when compared to pre-surgery levels. On average, the five patients showed an 8.2 point improvement in VCSS scores at one year, compared to pre-surgery levels. The improvements in VCSS scores is significant and indicates that VenoValve patients who had severe CVI pre-surgery, now have mild CVI or the complete absence of disease at one-year post surgery.

• Hancock Jaffe Announces Registered Direct Offering

  Yahoo

  27 апр 2020 г. в 12:31

  IRVINE, CA / ACCESSWIRE / April 27, 2020 / Hancock Jaffe Laboratories, Inc. (HJLI)(HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $1 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and one warrant to purchase one share of common stock will be $0.53, which is priced at-the-market under Nasdaq rules. Under the terms of the purchase agreement, HJLI has agreed to sell 1,886,800 shares of its common stock.

• Principal Investigator Dr. Jorge Hernando Ulloa Presents Updated VenoValve Data at the 32nd Annual Meeting of the American Venous Forum

  Yahoo

  05 мар 2020 г. в 13:31

  IRVINE, CA / ACCESSWIRE / March 5, 2020 / Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-man VenoValve study in Colombia, presented new VenoValve data at the 32nd Annual Meeting of the American Venous Forum ("AVF") at the Omni Amelia Island Plantation Hotel at Amelia Island, Florida. Dr. Ulloa's presentation included data on 8 VenoValve patients that are six months post VenoValve surgery (including one patient that is one year post surgery), 2 patients that are 90 days post-surgery, and 1 patient that is 60 days post-surgery.